Lun - Ven 8:00 - 17:00

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

Education environnementale
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

Ecotourisme
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

Développement Communautaire
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

ODDB ONG

Vardenafil 20mg - 4 Tablets

Other > vardenafil tablets


The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9 [see Dosage and Administration (2.4) and Warnings and Precautions (5.2).] Cobicistat with vardenafil hydrochloride orally disintegrating tablets can result in increased plasma concentrations.

What happens if the prescriber decides treatment is not suitable?

Vardenafil hydrochloride orally disintegrating tablets should not be used with cobicistat. Erythromycin (500 mg t.i.d.) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in vardenafil Cmax when co-administered with vardenafil 5 mg in healthy volunteers [see Dosage and Administration (2) and Warnings and Precautions (5)]. No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, an antacid based on magnesium-aluminum hydroxide, and ranitidine.

  • Vardenafil is used to treat erectile dysfunction in men.
  • It works by increasing blood flow to the penis.
  • Vardenafil is marketed under the brand name Levitra.
  • The drug typically takes effect within 25-60 minutes.

In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters. Cimetidine (400 mg b.i.d.) had no effect on AUC and Cmax of vardenafil when co-administered with 20 mg vardenafil in healthy volunteers.

  • Vardenafil is available in tablet form, usually 5-20 mg.
  • It is designed to be taken as needed, not regularly.
  • Effects may vary based on age and health condition.
  • Always follow your healthcare provider’s instructions.

The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 micromolar toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg vardenafil dose. In vitro data suggest that vardenafil has the potential to inhibit P-glycoprotein (P-gp) at therapeutic doses.

Product Dosage Quantity + Bonus Price
Viagra Professional100mg90 + 2 Pills207.09€ 197.23€
Kamagra Polo100mg272 + 12 Pills622.94€ 593.28€
Cialis Super Active20mg90 + 10 Pills314.14€ 299.18€
Cialis Original20mg34 + 2 Pills183.99€ 175.23€
Cialis Generic10mg180 + 8 Pills236.88€ 225.60€
Viagra Generic50mg180 + 8 Pills158.82€ 151.26€
Viagra Generic25mg60 + 4 Pills71.99€ 68.56€
Kamagra 100 mg100 mg84 + 6 Pills264.44€ 251.85€
Kamagra Soft Tabs100mg60 + 4 Pills180.59€ 171.99€
Levitra Original20mg34 + 2 Pills188.51€ 179.53€
Cialis Generic2.5mg20 Pills40.73€ 38.79€
Levitra Original20mg92 + 4 Pills406.22€ 386.88€
Levitra Generic60mg60 + 4 Pills198.85€ 189.38€
Viagra Generic200mg10 Pills40.96€ 39.01€
Viagra Generic150mg60 + 4 Pills111.25€ 105.95€
Levitra Professional20mg30 Pills119.12€ 113.45€
Levitra Original20mg12 Pills81.99€ 78.09€

Nifedipine: Vardenafil 20 mg (film-coated tablets), when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative AUC or Cmax of nifedipine, a drug that is metabolized via CYP3A4. Vardenafil hydrochloride orally disintegrating tablets, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily in patients whose hypertension was controlled with nifedipine, produced mean additional supine systolic/diastolic blood pressure reductions of 3/4 mmHg (age group 65 to 69 years) and 5/5 mmHg (age group 70 to 80 years) compared to placebo. indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively. Aspirin: Vardenafil 10 mg and 20 mg did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets). Other Interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).

5.5 Sudden Hearing Loss

Vardenafil is present in rat milk of lactating rats (see Data). Vardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. Following a single oral dose of 3 mg/kg, 3.3% of the administered dose was excreted into the milk within 24 hours. Vardenafil hydrochloride orally disintegrating tablets are not indicated for use in pediatric patients. Safety and efficacy in children has not been established.

What should I know about vardenafil before taking it?

Vardenafil AUC and Cmax in elderly males 65 years or older taking vardenafil hydrochloride orally disintegrating tablets were increased by 39% and 21%, respectively, in comparison to patients aged 45 years and below. No overall differences in safety or effectiveness were observed between patients ≥65 years old and those < 65 years old in placebo-controlled clinical trials [see Clinical Pharmacology (12.3)]. Do not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate or severe hepatic impairment. In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects. 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryVardenafil hydrochloride orally disintegrating tablets are not indicated for use in females.There are no data with the use of vardenafil hydrochloride orally disintegrating tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, the maximum recommended human dose (MRHD) of 20 mg based on AUC(see Data).DataAnimal DataNo evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. This dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the AUC values for unbound vardenafil and its major metabolite in humans given the maximum recommended human dose (MRHD) of 20 mg.In the rat pre-and postnatal development study, the NOAEL (no observed adverse effect level) for maternal toxicity was 8 mg/kg/day. Retarded physical development of pups in the absence of maternal effects was observed following maternal exposure to 1 and 8 mg/kg possibly cenforce 200mg canada due to vasodilatation and/or secretion of the drug into milk. The number of living pups born to rats exposed pre- and postnatally was reduced at 60 mg/kg/day.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Based on the results of the pre- and postnatal study, the developmental NOAEL is less than 1 mg/kg/day. Based on plasma exposures in the rat developmental toxicity study, 1 mg/kg/day in the pregnant rat is estimated to produce total AUC values for unbound vardenafil and its major metabolite comparable to the human AUC at the MRHD of 20 mg.8.2 LactationRisk SummaryVardenafil hydrochloride orally disintegrating tablets are not indicated for use in females.There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Vardenafil is present in rat milk of lactating rats (see Data).DataVardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma.

How to save on vardenafil

Vardenafil is present in rat milk of lactating rats (see Data).DataVardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. Following a single oral dose of 3 mg/kg, 3.3% of the administered dose was excreted into the milk within 24 hours.8.4 Pediatric UseVardenafil hydrochloride orally disintegrating tablets are not indicated tadalista professional for use in pediatric patients. Safety and efficacy in children has not been established.8.5 Geriatric UseVardenafil AUC and Cmax in elderly males 65 years or older taking vardenafil hydrochloride orally disintegrating tablets were increased by 39% and 21%, respectively, in comparison to patients aged 45 years and below. No overall differences in safety or effectiveness were observed between patients ≥65 years old and those < 65 years old in placebo-controlled clinical trials [see Clinical Pharmacology (12.3)].8.6 Hepatic ImpairmentDo not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate or severe hepatic impairment.In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects. Vardenafil hydrochloride orally disintegrating tablets can be used in patients with mild hepatic impairment.

Dosage for people with kidney disease

In volunteers with moderate hepatic impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment. Do not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate to severe hepatic impairment [see Warnings and Precautions (5.8) and Dosage and Administration (2). ]8.7 Renal ImpairmentDo not use vardenafil hydrochloride orally disintegrating tablets in patients on renal dialysis.In volunteers with mild renal impairment (CLcr = 50 to 80 mL/min), the pharmacokinetics of vardenafil 20 mg film-coated tablets were similar to those observed in a control group with normal renal function. In the moderate (CLcr = 30 to 50 mL/min) or severe (CLcr <30 mL/min) renal impairment groups, the AUC of vardenafil was 20 to 30% higher compared to that observed in a control group with normal renal function (CLcr >80 mL/min). Following a single oral dose of 3 mg/kg, 3.3% of the administered dose was excreted into the milk within 24 hours.8.4 Pediatric UseVardenafil hydrochloride orally disintegrating tablets are not indicated tadalista professional for use in pediatric patients.

5.11 Effects on Bleeding

Vardenafil hydrochloride orally disintegrating tablets can be used in patients with mild, moderate or severe renal impairment. Do not use vardenafil hydrochloride orally disintegrating tablets in patients on renal dialysis as vardenafil has not been evaluated in such patients [see Dosage and Administration (2.3) and Warnings and Precautions (5.9)]. Vardenafil hydrochloride orally disintegrating tablets are not indicated for use in females. There are no data with the use of vardenafil hydrochloride orally disintegrating tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, the maximum recommended human dose (MRHD) of 20 mg based on AUC(see Data).

Professional resources

No evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis. This dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the libido booster women AUC values for unbound vardenafil and its major metabolite in humans given the maximum recommended human dose (MRHD) of 20 mg. In the rat pre-and postnatal development study, the NOAEL (no observed adverse effect level) for maternal toxicity was 8 mg/kg/day. Based on plasma exposures in the rat developmental toxicity study, 1 mg/kg/day in the pregnant rat is estimated to produce total AUC values for unbound vardenafil and its major metabolite comparable to the human AUC at the MRHD of 20 mg. There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Safety and efficacy in children has not been established.8.5 Geriatric UseVardenafil AUC and Cmax in elderly males 65 years or older taking vardenafil hydrochloride orally disintegrating tablets were increased by 39% and 21%, respectively, in comparison to patients aged 45 years and below. No overall differences in safety or effectiveness were observed between patients ≥65 years old and those < 65 years old in placebo-controlled clinical trials [see Clinical Pharmacology (12.3)].8.6 Hepatic ImpairmentDo not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate or severe hepatic impairment.In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects.

Usual Geriatric Dose for Erectile Dysfunction

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9 [see Dosage and Administration (2.4) and Warnings and Precautions (5.2).] Cobicistat with vardenafil hydrochloride orally disintegrating tablets can result in increased plasma concentrations. Vardenafil hydrochloride orally disintegrating tablets should not be used with cobicistat. Erythromycin (500 mg t.i.d.) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in vardenafil Cmax when co-administered with vardenafil 5 mg in healthy volunteers [see Dosage and Administration (2) and Warnings and Precautions (5)]. No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, an antacid based on magnesium-aluminum hydroxide, and ranitidine. In the warfarin study, vardenafil had no effect on the prothrombin time or other pharmacodynamic parameters.

Related treatment guides

Cimetidine (400 mg b.i.d.) had no effect on AUC and Cmax of vardenafil when co-administered with 20 mg vardenafil in healthy volunteers. The most potent inhibitory activity was observed for vardenafil metabolite M1, which had a Ki of 1.4 micromolar toward CYP3A4, which is about 20 times higher than the M1 Cmax values after an 80 mg vardenafil dose. In vitro data suggest that vardenafil has the potential to inhibit P-glycoprotein (P-gp) at therapeutic doses. Nifedipine: Vardenafil 20 mg (film-coated tablets), when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative AUC or Cmax of nifedipine, a drug that is metabolized via CYP3A4. Vardenafil hydrochloride orally disintegrating tablets, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily in patients whose hypertension was controlled with nifedipine, produced mean additional supine systolic/diastolic blood pressure reductions of 3/4 mmHg (age group 65 to 69 years) and 5/5 mmHg (age group 70 to 80 years) compared to placebo. Vardenafil hydrochloride orally disintegrating tablets can be used in patients with mild hepatic impairment. In volunteers with moderate hepatic impairment (Child-Pugh B), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 130% and 160%, respectively, compared to healthy control subjects. Vardenafil has not been evaluated in patients with severe (Child-Pugh C) hepatic impairment. Do not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate to severe hepatic impairment [see Warnings and Precautions (5.8) and Dosage and Administration (2). ]8.7 Renal ImpairmentDo not use vardenafil hydrochloride orally disintegrating tablets in patients on renal dialysis.In volunteers with mild renal impairment (CLcr = 50 to 80 mL/min), the pharmacokinetics of vardenafil 20 mg film-coated tablets were similar to those observed in a control group with normal renal function. In the moderate (CLcr = 30 to 50 mL/min) or severe (CLcr <30 mL/min) renal impairment groups, the AUC of vardenafil was 20 to 30% higher compared to that observed in a control group with normal renal function (CLcr >80 mL/min). Vardenafil hydrochloride orally disintegrating tablets can be used in patients with mild, moderate or severe renal impairment. Do not use vardenafil hydrochloride orally disintegrating tablets in patients on renal dialysis as vardenafil has not been evaluated in such patients [see Dosage and Administration (2.3) and Warnings and Precautions (5.9)]. Vardenafil hydrochloride orally disintegrating tablets are not indicated for use in females. There are no data with the use of vardenafil hydrochloride orally disintegrating tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, the maximum recommended human dose (MRHD) of 20 mg based on AUC(see Data). No evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis.

Important Notes

indinavir, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively. Aspirin: Vardenafil 10 mg and 20 mg did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets). Other Interactions: Vardenafil had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters). 8 USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk SummaryVardenafil hydrochloride orally disintegrating tablets are not indicated for use in females.There are no data with the use of vardenafil hydrochloride orally disintegrating tablets in pregnant women to inform any drug-associated risks. In animal reproduction studies conducted in pregnant rats and rabbits, no adverse developmental outcomes were observed with oral administration of vardenafil during organogenesis at exposures for unbound vardenafil and its major metabolite at approximately 100 and 29 times, respectively, the maximum recommended human dose (MRHD) of 20 mg based on AUC(see Data).DataAnimal DataNo evidence of specific potential for teratogenicity, embryotoxicity or fetotoxicity was observed in rats and rabbits that received vardenafil at up to 18 mg/kg/day during organogenesis.

Incidence not known

This dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the AUC values for unbound vardenafil and its major metabolite in humans given the maximum recommended human dose (MRHD) of 20 mg.In the rat pre-and postnatal development study, the NOAEL (no observed adverse effect level) for maternal toxicity was 8 mg/kg/day. Retarded physical development of pups in the absence of maternal effects was observed following maternal exposure to 1 and 8 mg/kg possibly cenforce 200mg canada due to vasodilatation and/or secretion of the drug into milk. The number of living pups born to rats exposed pre- and postnatally was reduced at 60 mg/kg/day. Based on the results of the pre- and postnatal study, the developmental NOAEL is less than 1 mg/kg/day. Based on plasma exposures in the rat developmental toxicity study, 1 mg/kg/day in the pregnant rat is estimated to produce total AUC values for unbound vardenafil and its major metabolite comparable to the human AUC at the MRHD of 20 mg.8.2 LactationRisk SummaryVardenafil hydrochloride orally disintegrating tablets are not indicated for use in females.There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. This dose is approximately 100 fold (rat) and 29 fold (rabbit) greater than the libido booster women AUC values for unbound vardenafil and its major metabolite in humans given the maximum recommended human dose (MRHD) of 20 mg. In the rat pre-and postnatal development study, the NOAEL (no observed adverse effect level) for maternal toxicity was 8 mg/kg/day.

Study/Source Sample Size Success Rate Notes
Clinical Trial A 150 men 80% Significant improvement in erectile function
Clinical Trial B 200 men 75% Better outcomes with 10 mg dose compared to placebo
Real-world Reports 300 patients 78% Effective in various age groups and conditions

Based on plasma exposures in the rat developmental toxicity study, 1 mg/kg/day in the pregnant rat is estimated to produce total AUC values for unbound vardenafil and its major metabolite comparable to the human AUC at the MRHD of 20 mg. There is no information on the presence of vardenafil and its major metabolite in human milk, the effects on the breastfed infant, or the effects on milk production. Vardenafil is present in rat milk of lactating rats (see Data). Vardenafil was secreted into the milk of lactating rats at concentrations approximately 10-fold greater than found in the plasma. Following a single oral dose of 3 mg/kg, 3.3% of the administered dose was excreted into the milk within 24 hours. Vardenafil hydrochloride orally disintegrating tablets are not indicated for use in pediatric patients. Safety and efficacy in children has not been established.

  • Unlike some ED medications, vardenafil may work in the presence of fatty foods.
  • It requires sexual stimulation to produce an effect.
  • Alcohol can increase the risk of side effects.
  • Avoid combining with recreational drugs.

Vardenafil AUC and Cmax in elderly males 65 years or older taking vardenafil hydrochloride orally disintegrating tablets were increased by 39% and 21%, respectively, in comparison to patients aged 45 years and below. No overall differences in safety or effectiveness were observed between patients ≥65 years old and those < 65 years old in placebo-controlled clinical trials [see Clinical Pharmacology (12.3)].

  • Vardenafil should be stored at room temperature.
  • Keep out of reach of children and pets.
  • Notify your doctor if you experience priapism.
  • Use only the prescribed dose to prevent adverse effects.

Do not use vardenafil hydrochloride orally disintegrating tablets in patients with moderate or severe hepatic impairment. In volunteers with mild hepatic impairment (Child-Pugh A), the Cmax and AUC following a 10 mg vardenafil (film-coated tablets) dose were increased by 22% and 17%, respectively, compared to healthy control subjects.

 Singes à ventre roux

10+

Années d'expérience

ODDB ONG

Domaines d'interventions

Les objectifs que
nous poursuivons

Dans le cadre de notre stratégie, nous menons des actions locales dans les différentes écorégions cruciales, en visant des objectifs globaux.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Biodiversité

Parce que chaque espèce joue un rôle particulier dans l’écosystème, elle est précieuse

En savoir plus
Education environnementale

L'éducation environnementale sensibilise, surtout les jeunes, à nos ressources et à leur usage durable.

En savoir plus
Ecotourisme

L'écotourisme préserve la nature, implique les communautés locales et offre des expériences durables.

En savoir plus
Développement Communautaire

Moins dépendance forestière, plus de sécurité alimentaire, préservation des ressources.

En savoir plus
ODDB ONG

Nos Projets

ODDB-ONG agit pour l'environnement et le mieux-être des communautés locales.

ODDB-ONG mène des actions écologiques pour soutenir les populations locales dans leurs efforts pour améliorer leur bien-être et celui de leur environnement.

Nous voulons nous assurer que les espèces les plus emblématiques et les plus menacées soient préservées et puissent évoluer librement dans la nature. Nous plaidons également pour le renforcement de l'intégrité de nos forêts les plus importantes et des avantages qu'elles procurent en termes de bien-être. Nous nous battons également pour que les futurs systèmes alimentaires soient durables et conformes aux critères de santé alimentaire. Enfin, il est nécessaire d'opérer une transition mondiale vers un avenir à faible émission de carbone.

Merci de soutenir nos projets

Votre don nous permet d’agir, merci !

ODDB ONG

Question à nous poser

Une question d'ordre général ?

La biodiversité fait référence à la variété et à la diversité de la vie sur Terre, y compris toutes les espèces d'animaux, de plantes, de micro-organismes et les écosystèmes dans lesquels ils vivent. Cela englobe la richesse génétique au sein des espèces, la diversité des espèces elles-mêmes et la variété des habitats naturels. En résumé, la biodiversité représente la variété de la vie et des écosystèmes qui rendent notre planète unique et fonctionnelle.

Pour poursuivre nos actions pour la planète et en engager de nouvelles, nous sollicitons le soutien de tous. Chaque contribution est importante. Partagez nos campagnes, faites un don, devenez bénévole pour ODDB ONG et aidez-nous à préserver la nature.

Le logo du ODDB ONG est une marque internationale déposée et soumise au droit d'auteur. Toute utilisation ou reproduction est strictement interdite sans autorisation. Si vous souhaitez utiliser le logo dans le cadre d'un partenariat, veuillez écrire à l'adresse suivante. Pour toute autre utilisation, veuillez contacter l'adresse suivante.

Pour toute demande de stage, veuillez consulter régulièrement notre page dédiée au recrutement.

Pour commencer, il est essentiel d'adopter de bonnes habitudes quotidiennes : privilégier une alimentation équilibrée avec moins de protéines animales et favorisant les circuits courts, opter pour des modes de transport durables tels que les transports en commun ou le vélo, améliorer votre efficacité énergétique et votre utilisation numérique, et réduire la production de déchets. Toutes ces pratiques sont détaillées dans la section " Agir au quotidien".

Un accusé de réception vous est envoyé par mail pour vous confirmer la réception de votre dossier de candidature.

Les conséquences de la crise écologique sont manifestes : une agriculture en déclin, des plans d'eau épuisés, un accès difficile à l'eau douce et des forêts en difficulté pour préserver la biodiversité. Notre enjeu environnemental majeur est clair : l'urgence d'agir. Cette nécessité ne concerne plus seulement les générations futures, mais également la population actuelle, qui subit déjà les perturbations profondes engendrées par la crise écologique.
singe a ventre rouge
ODDB ONG

Galerie

Nos Actions En Image

Dendroaspis jamesoni
ODDB ONG
Dendroaspis jamesoni
Benin Potto (Perodicticus potto juju)
ODDB ONG
Benin Potto (Perodicticus potto juju)
Singe tantale (Chlorocebus aethiops tantalus)
ODDB ONG
Singe tantale (Chlorocebus aethiops tantalus)
Female Sitatunga with offspring (Tragelaphus spekii)
ODDB ONG
Female Sitatunga with offspring (Tragelaphus spekii)
Cercopithecus aethiops tantalus
ODDB ONG
Cercopithecus aethiops tantalus
Coucal noir (Centropus senegalensis)
ODDB ONG
Coucal noir (Centropus senegalensis)
Cercopithecus erythrogaster
ODDB ONG
Cercopithecus erythrogaster
Female sitatunga (Tragelaphus spekii)
ODDB ONG
Female sitatunga (Tragelaphus spekii)
Gnanhouizoun community forest, Ouémé valley
ODDB ONG
Gnanhouizoun community forest, Ouémé valley
chouette
ODDB ONG
chouette
Héron cendré (Ardea cinerea)
ODDB ONG
Héron cendré (Ardea cinerea)
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
ODDB ONG
Apercu de l'entrée du village Gnanhouizounmè Apercu de l'entrée du village Gnanhouizounmè Saison sèche
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
ODDB ONG
Jacana à poitrine dorée (Actophilormis africana) Gnanhouizounmè_Bonou
Gnanhouizounmè au couché de soleil
ODDB ONG
Gnanhouizounmè au couché de soleil
Chamaeleo necasi
ODDB ONG
Chamaeleo necasi
Aigrette
ODDB ONG
Aigrette

Nos Statistiques

ODDB en chiffres

10+

10+

Années d'expérience

79

79Ha

de superficies reboisées

14K+

14K+

personnes sensibilisées

320

320

personnes autonomisées

151

151

Stagiaires et bénévoles formés pour suivi de la biodiversité

ODDB ONG

Nos Actualités

Actualités

Nos  Partenaires

Partenaires Techniques

little green guards Chester Zoo Institut des Tortues d'Afrique Conservatoire pour la Protection des Primates National Geographic

Partenaires Financiers

Primate Society of Great Britain SUCO INTERNATIONAL BENIN UP2GREEN The Rufford Foundation IKI